Ind-Swift Laboratories (NSE:INDSWFTLAB) Cyclically Adjusted Revenue per Share: ₹234.87 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INDSWFTLAB Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
53 GF Score
Price ₹231.47
GF Value ₹36.72
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ind-Swift Laboratories Cyclically Adjusted Revenue per Share?

Ind-Swift Laboratories NSE:INDSWFTLAB -1.03% 53 Cyclically Adjusted Revenue per Share is ₹234.87 as of Mar. 2026. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 53/100 and a GF Value™ of ₹36.72 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ind-Swift Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₹19.774. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹234.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ind-Swift Laboratories's average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-17), Ind-Swift Laboratories's current stock price is ₹231.47. Ind-Swift Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹234.87. Ind-Swift Laboratories's Cyclically Adjusted PS Ratio of today is 0.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ind-Swift Laboratories was 1.05. The lowest was 0.29. And the median was 0.45.


Ind-Swift Laboratories  (NSE:INDSWFTLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ind-Swift Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=231.47/234.87
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ind-Swift Laboratories was 1.05. The lowest was 0.29. And the median was 0.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ind-Swift Laboratories Cyclically Adjusted Revenue per Share Related Terms


Ind-Swift Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ind-Swift Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ind-Swift Laboratories Cyclically Adjusted Revenue per Share Chart

Ind-Swift Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 239.88 234.87

Ind-Swift Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 243.75 239.88 241.33 238.20 234.87

NSE:INDSWFTLAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:INDSWFTLAB
53GF Score
Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ind-Swift Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ind-Swift Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.774/164.2724*164.2724
=19.774

Current CPI (Mar. 2026) = 164.2724.

Ind-Swift Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201206 77.083 79.567 159.145
201209 83.516 82.244 166.813
201212 59.210 83.774 116.104
201303 67.687 85.687 129.764
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 40.861 111.317 60.300
201809 33.174 115.142 47.329
201812 37.290 115.142 53.201
201903 34.087 118.202 47.373
201906 39.439 120.880 53.597
201909 40.272 123.175 53.709
201912 42.709 126.235 55.578
202003 33.295 124.705 43.859
202006 35.411 127.000 45.803
202009 38.651 130.118 48.796
202012 38.204 130.889 47.948
202103 38.276 131.771 47.717
202106 42.245 134.084 51.756
202109 39.867 135.847 48.209
202112 41.698 138.161 49.579
202203 51.898 138.822 61.413
202206 47.354 142.347 54.648
202209 52.511 144.661 59.630
202212 52.877 145.763 59.592
202303 51.458 146.865 57.557
202306 52.556 150.280 57.449
202309 49.052 151.492 53.190
202312 48.711 152.924 52.326
202403 139.131 153.035 149.348
202406 5.672 155.789 5.981
202409 21.957 157.882 22.846
202412 19.230 158.323 19.953
202503 20.010 157.552 20.864
202509 18.340 162.289 18.564
202512 17.872 163.281 17.981
202603 19.774 164.272 19.774

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹234.87 mean?
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a Cyclically Adjusted Revenue per Share of ₹234.87 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ind-Swift Laboratories and its competitors.
Is Ind-Swift Laboratories' Cyclically Adjusted Revenue per Share too high?
Ind-Swift Laboratories' current Cyclically Adjusted Revenue per Share is ₹234.87. Overall, Ind-Swift Laboratories has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Ind-Swift Laboratories' Cyclically Adjusted Revenue per Share of ₹234.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ind-Swift Laboratories and its competitors. Ind-Swift Laboratories's current Cyclically Adjusted Revenue per Share is ₹234.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹36.72, compared to a current price of ₹231.47 — trading 530.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹234.87. Ind-Swift Laboratories' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current Cyclically Adjusted Revenue per Share is ₹234.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued. The current stock price of ₹231.47 is trading 530.4% above its estimated GF Value™ of ₹36.72. GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:INDSWFTLAB:

  • Cyclically Adjusted Revenue per Share: ₹234.87
  • GF Value™: ₹36.72 vs. price of ₹231.47 (530.4% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ind-Swift Laboratories Business Description

Other Exchanges 532305:India
Address SCO 850, NAC, Shivalik Enclave, Manimajra, Chandigarh, PB, IND, 160101
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
53GF Score

Get the complete analysis for NSE:INDSWFTLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹231.47
Price
₹36.72
GF Value